NCT00200447

Brief Summary

This study conducted to more fully evaluate the way that carbidopa/levodopa and entacapone may work in the brain. This research study uses \[123I\]-IBZM and dynamic SPECT imaging to determine the amount and the duration of dopamine release from specific regions in the brain after treatment with either the combination of carbidopa/levodopa or the combination of carbidopa/levodopa/entacapone.

Trial Health

100
On Track

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Enrollment
3

participants targeted

Target at below P25 for phase_2

Timeline
Completed

Started Mar 2004

Shorter than P25 for phase_2

Status
completed

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

Study Start

First participant enrolled

March 1, 2004

Completed
6 months until next milestone

Primary Completion

Last participant's last visit for primary outcome

September 1, 2004

Completed
Same day until next milestone

Study Completion

Last participant's last visit for all outcomes

September 1, 2004

Completed
1 year until next milestone

First Submitted

Initial submission to the registry

September 12, 2005

Completed
8 days until next milestone

First Posted

Study publicly available on registry

September 20, 2005

Completed
Last Updated

January 21, 2008

Status Verified

January 1, 2008

Enrollment Period

6 months

First QC Date

September 12, 2005

Last Update Submit

January 17, 2008

Conditions

Parkinson's Disease

Keywords

Parkinsonbrain imaging

Outcome Measures

Primary Outcomes (1)

  • The primary outcome will be the reduction from baseline in IBZM striatal uptake during a 6-8 hour assessment period after treatment.

    6-8hrs

Secondary Outcomes (1)

  • Secondary Measures include: Putamen and caudate uptake over time, UPDRS scores, and Pharmacokinetic analysis.

    6-8hrs

Interventions

carbidopa/l-dopaDRUG
carbidopa/l-dopa/entacaponeDRUG
StalevoDRUG
[123I]-IBZM imagingPROCEDURE

Eligibility Criteria

Age30 Years+
Sexall
Healthy VolunteersNo
Age GroupsAdult (18-64), Older Adult (65+)

You may qualify if:

  • The patient is aged 30 years or older.
  • Written informed consent is obtained.
  • Patients have a diagnosis of idiopathic Parkinson's disease.
  • Hoehn and Yahr stages for patients are I-III.
  • Patients have a diagnosis\> 4 yrs prior to screening
  • Patients are treated with carbidopa/levodopa with \> 300 mg levodopa.

You may not qualify if:

  • The patient has atypical or drug-induced Parkinson's disease.
  • The patient has dementia (MMSE 24).
  • The patient has a clinically significant clinical laboratory values, and/or medical or psychiatric illness.
  • The patient has any disorder that may interfere with drug absorption, distribution, metabolism, or excretion (including gastrointestinal surgery).
  • The patient has evidence of clinically significant gastrointestinal, cardiovascular, hepatic, renal, hematological, neoplastic, endocrine, neurological, immunodeficiency, pulmonary, or other disorder or disease.
  • The patient has been treated with a dopamine agonist within the past 30 days.
  • Concomitant treatment with Monoamine Oxidase (MAO)-inhibitors (except selegiline \<10 mg/day) within 30 days prior to the screening visit
  • Patient has a history of iodine allergy

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Related Publications (5)

  • Castner SA, al-Tikriti MS, Baldwin RM, Seibyl JP, Innis RB, Goldman-Rakic PS. Behavioral changes and [123I]IBZM equilibrium SPECT measurement of amphetamine-induced dopamine release in rhesus monkeys exposed to subchronic amphetamine. Neuropsychopharmacology. 2000 Jan;22(1):4-13. doi: 10.1016/S0893-133X(99)00080-9.

    PMID: 10633485BACKGROUND

  • de la Fuente-Fernandez R, Lu JQ, Sossi V, Jivan S, Schulzer M, Holden JE, Lee CS, Ruth TJ, Calne DB, Stoessl AJ. Biochemical variations in the synaptic level of dopamine precede motor fluctuations in Parkinson's disease: PET evidence of increased dopamine turnover. Ann Neurol. 2001 Mar;49(3):298-303. doi: 10.1002/ana.65.abs.

    PMID: 11261503BACKGROUND

  • Laruelle M, D'Souza CD, Baldwin RM, Abi-Dargham A, Kanes SJ, Fingado CL, Seibyl JP, Zoghbi SS, Bowers MB, Jatlow P, Charney DS, Innis RB. Imaging D2 receptor occupancy by endogenous dopamine in humans. Neuropsychopharmacology. 1997 Sep;17(3):162-74. doi: 10.1016/S0893-133X(97)00043-2.

    PMID: 9272483BACKGROUND

  • Seibyl JP, Woods SW, Zoghbi SS, Baldwin RM, Dey HM, Goddard AW, Zea-Ponce Y, Zubal G, Germine M, Smith EO, et al. Dynamic SPECT imaging of dopamine D2 receptors in human subjects with iodine-123-IBZM. J Nucl Med. 1992 Nov;33(11):1964-71.

    PMID: 1432157BACKGROUND

  • Seibyl JP, Zea-Ponce Y, Brenner L, Baldwin RM, Krystal JH, Offord SJ, Mochoviak S, Charney DS, Hoffer PB, Innis RB. Continuous intravenous infusion of iodine-123-IBZM for SPECT determination of human brain dopamine receptor occupancy by antipsychotic agent RWJ-37796. J Nucl Med. 1996 Jan;37(1):11-5.

    PMID: 8543979BACKGROUND

MeSH Terms

Conditions

Parkinson Disease

Interventions

Stalevo

Condition Hierarchy (Ancestors)

Parkinsonian DisordersBasal Ganglia DiseasesBrain DiseasesCentral Nervous System DiseasesNervous System DiseasesMovement DisordersSynucleinopathiesNeurodegenerative Diseases

Study Officials

  • John P Seibyl, MD

    Molecular NeuroImaging

    PRINCIPAL INVESTIGATOR

Study Design

Study Type
interventional
Phase
phase 2
Allocation
RANDOMIZED
Masking
NONE
Purpose
TREATMENT
Intervention Model
CROSSOVER
Sponsor Type
OTHER

Study Record Dates

First Submitted

September 12, 2005

First Posted

September 20, 2005

Study Start

March 1, 2004

Primary Completion

September 1, 2004

Study Completion

September 1, 2004

Last Updated

January 21, 2008

Record last verified: 2008-01